These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
538 related articles for article (PubMed ID: 11093076)
1. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800 [TBL] [Abstract][Full Text] [Related]
3. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495 [TBL] [Abstract][Full Text] [Related]
4. Differing profiles of prostaglandin formation inhibition between selective prostaglandin H synthase-2 inhibitors and conventional NSAIDs in inflammatory and non-inflammatory sites of the rat. Harada Y; Kawamura M; Hatanaka K; Saito M; Ogino M; Ohno T; Ogino K; Yang Q Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):345-58. PubMed ID: 9653772 [TBL] [Abstract][Full Text] [Related]
5. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Engelhardt G; Bögel R; Schnitzler C; Utzmann R Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265 [TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894 [TBL] [Abstract][Full Text] [Related]
7. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study. Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128 [TBL] [Abstract][Full Text] [Related]
8. Effects of selective and unselective cyclooxygenase inhibitors on prostanoid release from various rat organs. Tegeder I; Neupert W; Gühring H; Geisslinger G J Pharmacol Exp Ther; 2000 Mar; 292(3):1161-8. PubMed ID: 10688636 [TBL] [Abstract][Full Text] [Related]
9. The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa. Tavares IA Aliment Pharmacol Ther; 2000 Jun; 14(6):795-9. PubMed ID: 10848664 [TBL] [Abstract][Full Text] [Related]
10. Effects of aminoguanidine and cyclooxygenase inhibitors on nitric oxide and prostaglandin production, and nitric oxide synthase and cyclooxygenase expression induced by lipopolysaccharide in the estrogenized rat uterus. Ribeiro M; Cella M; Farina M; Franchi A Neuroimmunomodulation; 2004; 11(3):191-8. PubMed ID: 15067210 [TBL] [Abstract][Full Text] [Related]
11. Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats. Nakatsugi S; Terada N; Yoshimura T; Horie Y; Furukawa M Prostaglandins Leukot Essent Fatty Acids; 1996 Dec; 55(6):395-402. PubMed ID: 9014217 [TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. Pairet M; van Ryn J; Schierok H; Mauz A; Trummlitz G; Engelhardt G Inflamm Res; 1998 Jun; 47(6):270-6. PubMed ID: 9683035 [TBL] [Abstract][Full Text] [Related]
13. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505 [TBL] [Abstract][Full Text] [Related]
14. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. King JN; Rudaz C; Borer L; Jung M; Seewald W; Lees P Res Vet Sci; 2010 Jun; 88(3):497-506. PubMed ID: 20004922 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Gilroy DW; Tomlinson A; Willoughby DA Eur J Pharmacol; 1998 Aug; 355(2-3):211-7. PubMed ID: 9760036 [TBL] [Abstract][Full Text] [Related]
17. Role of prostaglandin H synthase-2 in prostaglandin E2 formation in rat carrageenin-induced pleurisy. Harada Y; Hatanaka K; Kawamura M; Saito M; Ogino M; Majima M; Ohno T; Ogino K; Yamamoto K; Taketani Y; Yamamoto S; Katori M Prostaglandins; 1996 Jan; 51(1):19-33. PubMed ID: 8900441 [TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. Liu XH; Kirschenbaum A; Lu M; Yao S; Dosoretz A; Holland JF; Levine AC J Biol Chem; 2002 Dec; 277(51):50081-6. PubMed ID: 12401798 [TBL] [Abstract][Full Text] [Related]